VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis
© Huang et al.; licensee BioMed Central Ltd. 2013
Received: 11 December 2012
Accepted: 2 May 2013
Published: 21 May 2013
Retroperitoneal lymph node (RLN) metastasis is an important indicator of endometrial cancer (EC) prognosis. Because vascular endothelial growth factor c (VEGF-c) is known to influence lymphangiogenesis and thereby lymph node metastasis, this study assessed the relationship of VEGF-c mRNA expression with RLN metastasis in EC.
The uterine muscularis mucosae of New Zealand white rabbits were inoculated with a VX2 tumor cell suspension after which they were sacrificed at 15, 18, 21, 24, 27 and 30 days. Control groups consisted of those receiving no treatment or an injection of saline. EC and metastatic RLN tissues along with peripheral blood samples were collected, and VEGF-c mRNA expression was evaluated using fluorescence real-time quantitative PCR.
The establishment of an in vivo model of EC with complete RLN metastasis was pathologically confirmed at day 21 post-injection with VX2 cells. As compared to the control groups, VEGF-c mRNA expression increased significantly over time in the tumor site, RLN, and peripheral white blood cells of EC rabbits. Significantly higher VEGF-c mRNA expression was observed in metastatic RLNs as compared to those without metastasis (P < 0.001). In addition, increased VEGF-c mRNA expression was observed in peripheral white blood cells of rabbits with RLN metastasis (P < 0.002).
Injection of a VX2 cell suspension is a simple method of establishing an in vivo EC model. VEGF-c may play an important role in the development of EC and its metastasis to RLN and may be useful marker to predict RLN metastasis.
KeywordsVascular endothelial growth factor c Endometrial cancer Fluorescence real-time quantitative PCR Disease animal model Animal Rabbit
Endometrial cancer (EC) is one of the most common malignancies of the female reproductive system . Whereas patients with early-stage EC have a good prognosis, those with advanced EC usually develop retroperitoneal lymph node (RLN) metastasis with a 5-year survival rate, ranging from 30 to 40% [2–4]. Thus, it is crucial to develop new methods for predicting RLN metastasis in EC that can inform clinicians in selecting treatment modalities.
Analysis of a panel of angiogenic factors, including vascular endothelial growth factors (VEGF-A, -B, -C, D), matrix metalloproteinase-2 (MMP-2), and basic fibroblast growth factor (bFGF), in 16 gynecological cancer cell lines revealed that VEGF-c expression was significantly correlated with cell migration as well as MMP-2 levels . VEGF-c influences endothelial cell growth, migration and survival; its signaling is medicated by the VEGF receptors-2 and -3 (VEGFR-2 and VEGFR-3) on the surface of endothelial cells . VEGF-c also regulates lymphangiogenesis and promotes metastasis to lymph nodes as well as distant organs [6–8]. Because preoperative VEGF-c levels correlated with tumor stage and were an independent risk factor for survival in patients with certain types of EC , circulating VEGF-c levels may be useful as a prognostic tool to identify those EC patients most at risk for RLN metastasis. Furthermore, poorer prognosis was associated with VEGF-c expression in esophageal squamous cell carcinoma , and its upregulation was also noted in the metastasis of cervical  and colorectal  cancers.
In the present study, an in vivo model of RLN metastasis of EC was established by injecting a VX2 tumor cell suspension into the myometrium of New Zealand white rabbits. Fluorescence real-time quantitative PCR (RT-PCR) was employed to detect VEGF-c mRNA expression in EC tissues, RLNs, and peripheral white blood cells at various time points after injection. These data may provide a theoretical basis for further studies to evaluate VEGF-c as a marker of RLN metastasis in EC.
A total of 49 female New Zealand white rabbits weighing 2-2.5 kg were purchased from the Huadong Xinhua Experimental Animal Center in Guangzhou (License No: 0098816). One rabbit was used as the source of VX2 tumor cells while the remaining animals were used to establish the in vivo model. The animals were individually housed, allowed free access to standard laboratory food and water, and subjected to daily 12-hour light and dark cycles. The animal protocol used in this study was approved by the Center’s Animal Welfare Committee of Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
VX2 cell isolation
VX2 cells were kindly purchased from the Cell Bank of the Sun Yat-sen University. Stocks of VX2 cells were mixed in 5 mL RPMI 1640, resulting in a VX2 solution of approximately 1 × 1010 cells/mL, 0.2 mL of the cell suspension was injected into the quadriceps femoris of one rabbit. After 21 days, a solid mass was removed from the injection site, washed in normal saline, and placed in RPMI 1640. Areas with active growth were selected, and the tissue was cut into pieces of 0.5-1 mm in diameter. After vortexing, the solution (1 × 1010 cells/mL) was transferred to a syringe with a lumbar puncture needle.
Establishment of an animal model of EC with RLN metastasis
Animals in the experimental group were anesthetized with 3% pentobarbital sodium at 1 mL/kg via the ear vein and then placed in a supine position. After sterilization, a mid-line incision was made on the lower abdomen. After the uterus was exposed, 0.5 mL of the VX2 cell solution (1 × 1010 cells/mL) was injected into the muscularis mucosae of the myometrium 1 cm away from the cervix. The injection site was sutured, and the wound was closed with a 1-0 suture.
Six animals in the normal control group were randomly selected; they did not receive anesthesia or surgery. For the saline group, six rabbits received an injection of 0.5 mL of normal saline into the muscularis mucosae of the myometrium in place of the VX2 cell solution.
Sample collection and pathological examination
At 15, 18, 21, 24, 27 and 30 days post-injection of the VX2 cell solution, rabbits were sacrificed by aeroembolism (injection of air into the ear vein) (n = 6 per time point). At 30 days, animals in the normal control and saline groups were sacrificed by the same method. EC and RLN tissues were observed macroscopically, and the long diameter (a) and short diameter (b) were measured to calculate EC and RLN volume using the following equation: V = a × b2/2. Under aseptic conditions, the uterus, EC, and RLNs were collected. Half of the tissue was placed in Trizol (Invitrogen, CA, USA) and stored in liquid nitrogen and then at -80°C, and the other half was fixed in 10% formalin and embedded in paraffin. Sections were obtained and stained with hematoxylin and eosin (H&E). The stained EC and metastatic RLN tissues were independently observed under a light microscope by two pathologists, who were blinded to the treatment conditions.
At the time of sacrifice, a blood sample was also collected, incubated with a blood cell separation solution, Histopaque-1107 (Sigma Aldrich, St. Louis, MO, USA), and centrifuged at 3500 r/min for 10 min. The white blood cells were collected and stored at -80°C for extraction of RNA.
As previously mentioned, metastasis was confirmed by histopathology of the RLNs after different time points (n = 6 per time point). A group of six rabbits at a particular time point was considered “non-metastatic” if no metastasis was observed in all six animals. A group was considered to have “partial metastasis” if some animals had RLN metastasis while others did not. Finally, in those groups with “complete” metastasis, all six rabbits had RLN metastasis.
Real-time quantitative RT-PCR
RNA was extracted from 50-100 mg of the tissue samples and 100 μg of the white blood cells using Trizol. cDNA was obtained using the RNA samples (2 μg) and a RT-PCR kit (Promega Corporation, Madison, WI) following the manufacturer’s instructions, which produced a reaction mixture of 20 μL. The conditions for reverse transcription were 70°C for 5 min and 42°C for 60 min. The diluted cDNA (2 μL) was then used for real-time PCR using the Platinum SYBR green q-PCR Super Mix–UDG (Invitrogen, Carlsbad, CA) along with the following primers, which were designed with Premier 5.0 and synthesized by the Shanghai Yingwei Jieji Co., Ltd (Shanghai, China): VEGF-c: 5′ CCCCAAACCAGTAACAATCAGT 3′ (forward), 5′ CTGGCAGGGAGCGTCTAAT 3′ (reverse); and GAPDH: 5′ AGAGCACCAGAGGAGGACG 3′ (forward), 5′ TGGGATGGAAACTGTGAAGAG 3′ (reverse). The conditions for the fluorescence real-time quantitative PCR were as follows: 95°C for 2 min; 45 cycles of 95°C for 30 s, 58°C for 30 s and 72°C for 30 s; and 95°C for 1 min, 58°C for 30 s and 95°C for 30 s. The relative expression of VEGF-c was calculated as follows: ΔCt (target gene) = Ct (target gene) – Ct (GAPDH). ΔΔCt=ΔCt (target gene) - ΔCt (standard) mean of target gene. The relative copies of the target gene were determined as 2-ΔΔCt.
Continuous variables among more than two groups were compared by one-way analysis of variance (ANOVA). When a significant difference between groups was apparent, multiple comparisons of means were performed using the Bonferroni procedure with type-I error adjustment. Differences in VEGF-c mRNA expression between non-metastasized and metastasized RLNs were determined using an independent two sample t test. Data are presented as means ± standard deviation (SD). All statistical assessments were two-sided and evaluated at the 0.05 level of significant difference. Statistical analyses were performed using SPSS 15.0 statistics software (SPSS Inc, Chicago, IL).
Establishment of an animal model of EC with RLN metastasis
Development of RLN metastasis over time in an in vivo model of orthotopic endometrial cancer
The frequency of metastasized/examined lymph nodes (n = 6 per time point)
VEGF-c expression in the tumor, retroperitoneal lymph node, and peripheral white blood cells
Because RLN metastasis is an important factor in determining the prognosis of EC [2–4], the relationship between VEGF-c mRNA expression and RLN metastasis was evaluated in an in vivo model in the present study. The establishment of EC with RLN metastasis was confirmed at day 21 post-injection with VX2 cells. In addition, VEGF-c mRNA expression increased significantly over time in the tumor site, RLN tissue, and peripheral white blood cells. Metastatic RLNs expressed higher VEGF-c mRNA expression as compared to those without metastasis. Furthermore, significantly higher VEGF-c mRNA expression was observed in peripheral white blood cells of rabbits with RLN metastasis, indicating that VEGF-c levels may have predicative value for metastasis in EC.
The VX2 cell line is composed of squamous cell carcinoma cells derived from Shope virus-induced papilloma in rabbit . Their high survival rates make them a suitable candidate for in vivo inoculation , which has been carried out in liver, lung, uterus, and breast tissues to establish the corresponding animal models [14–16]. In the endometrium, inoculation of VX2 cells induced EC with lymph node metastasis after 14-21 days post-injection [14, 15], which is similar to the results of the present study. These previous studies employed blocks of VX2 cells in the myometrium using microsurgical instruments while the present study introduced the VX2 cells via an injection, which removes the dependence on microsurgical instruments, is less difficult, and may increase the success rate of establishing the model as was evident in the 100% success rate of establishing EC and RLN metastasis observed in this study. The high success rate of this study using this method is consistent with results reported by Chen et al. .
In addition to the advantage of a high success rate, the in vivo model of EC employed in the present study induced EC with lymph node metastasis by day 21, which was faster than that reported for other models. For example, establishment of a mouse model of EC with lymph node metastasis via 5 million HEC1A cells required eight weeks . Of note, 100% of the animals in the present study developed EC with RLN metastasis, which was greater than that observed using the HEC1A mouse model of 86.5% .
In the present study, an in vivo model of EC with RLN metastasis was established by injecting 500 million VX2 cells into the uterine muscularis mucosae of rabbits. Previous studies in our laboratory indicated that this number of cells was necessary for successful RLN metastasis (data not shown). Analysis of the peritoneal cavity revealed that primary tumors were restricted to within the uterus as peritoneal dissemination of the VX2 cells was not observed.
Tumor angiogenesis is related to its invasion and metastasis , and VEGF is an important factor regulating angiogenesis in cancers . The VEGF-c gene is mapped to chromosome 4q34 , and in vitro studies have confirmed that it induces lymphangiogenesis but not angiogenesis . Straume et al.  also reported that lymphatic vessel density in nodular melanoma was positively related to the VEGF-c level. Furthermore, previous studies have shown that the VEGF-c expression in solid cancers, including endometrial adenocarcinoma, was significantly higher than that observed in adjacent normal tissues [22–24], which is consistent with the data presented in this study. In patients with gastro-oesophageal junction adenocarcinoma, VEGF-c levels were associated with tumor stage, lymph node metastasis, and shorter periods of disease-free survival . Further studies will assess if the increase in VEGF-c expression is directly related to EC growth and metastasis through lymphangiogenesis. In addition, a possible synergism between VEGF-c and FGF-2 as reported by Cao et al.  will be explored.
In the present study, differences in VEGF-c mRNA expression were observed among rabbits without and with RLN metastasis; differences were also noted between rabbits with full and partial metastasis with the highest expression found in rabbits with metastasis to all RLNs. These results suggest that the increased VEGF-c may arise from the EC during its development and progression, which may subsequently promote lymph node metastasis . This data is consistent with that reported by Kimura et al.  in which VEGF-c levels correlated with lymph node metastasis and lymphatic involvement in esophageal squamous cell carcinoma. Although VEGF-c expression increased with tumor growth and RLN metastasis, further studies will evaluate whether its level is reflective of the cancer load and metastatic state of EC.
The current study was limited in that it did not confirm whether VEGF-c protein levels were correlated with those obtained for mRNA. Further studies will evaluate the VEGF-c protein levels, as well as markers of epithelial-mesenchymal transition (EMT), in tissues as well as serum samples using immunohistochemistry and enzyme-linked immunosorbent assays (ELISAs). In addition, although previous studies have reported a relationship between VEGF-c and lymphangiogenesis with metastasis [6–8], no mechanistic data were presented in this study. Finally, VEGF receptor expression was not determined.
Thus, an animal model of EC with RLN metastasis was established, which revealed an increase in VEGF-c mRNA expression in peripheral white blood cells with tumor growth and metastasis. Should further studies determine that VEGF-c levels are reflective of tumor load and metastatic state, examining serum VEGF-c levels may be useful for predicting RLN metastasis in EC patients and further inform clinicians as to the most effective treatment option, including intra-operative RLN dissection.
Analysis of variance
Enzyme-linked immunosorbent assays
Real-time quantitative PCR
Retroperitoneal lymph node
Vascular endothelial growth factor c
This study was funded by research grants from the Technology Project of Guangdong Province (No. 2011B031800219) and the Natural Science Foundation of Guangdong Province (No. 10451008901006144).
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.View ArticlePubMed
- Irvin WP, Rice LW, Berkowitz RS: Advances in the management of endometrial adenocarcinoma. J Rep rod Med. 2002, 47: 173-189.
- Havrilesky LJ, Cragun MJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A: Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005, 99: 689-695. 10.1016/j.ygyno.2005.07.014.View ArticlePubMed
- Nomura H, Aoki D, Suzuki N, Susumu N, Suzuki A, Tamada Y, Kataoka F, Higashiguchi A, Ezawa S, Nozawa S: Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer. Int J Gynecol Cancer. 2006, 16: 799-804. 10.1111/j.1525-1438.2006.00529.x.View ArticlePubMed
- Ueda M, Terai Y, Kumagai K, Ueki K, Yamaguchi H, Akise D, Ueki M: Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol. 2001, 82: 162-166. 10.1006/gyno.2001.6229.View ArticlePubMed
- Achen MG, Stacker SA: Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int J Cancer. 2006, 119: 1755-1760. 10.1002/ijc.21899.View ArticlePubMed
- Roy H, Bhardwaj S, Ylä-Herttuala S: Biology of vascular endothelial growth factors. FEBS Lett. 2006, 580: 2879-2887. 10.1016/j.febslet.2006.03.087.View ArticlePubMed
- Takahashi K, Saga Y, Mizukami H, Takei Y, Urabe M, Kume A, Suzuki M, Ozawa K: Development of a mouse model for lymph node metastasis with endometrial cancer. Cancer Sci. 2011, 102: 2272-2277. 10.1111/j.1349-7006.2011.02099.x.View ArticlePubMed
- Dobrzycka B, Terlikowski SJ, Kowalczuk O, Kulikowski M, Niklinski J: Serum levels of VEGF and VEGF-C in patients with endometrial cancer. Eur Cytokine Netw. 2011, 22: 45-51.PubMed
- Kimura Y, Watanabe M, Ohga T, Saeki H, Kakeji Y, Baba H, Maehara Y: Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 2003, 10: 1747-1751.PubMed
- Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M, Creasman WT: Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol. 2005, 98: 467-483. 10.1016/j.ygyno.2005.05.003.View ArticlePubMed
- Kawakami M, Furuhata T, Kimura Y, Yamaguchi K, Hata F, Sasaki K, Hirata K: Quantification of vascular endothelial growth factor-C and its receptor-3 messenger RNA with real-time quantitative polymerase chain reaction as a predictor of lymph node metastasis in human colorectal cancer. Surgery. 2003, 133: 300-308. 10.1067/msy.2003.45.View ArticlePubMed
- Kidd JG, Rous P: A transplantable rabbit carcinoma originating in a virus induced papilloma and containing the virus in masked or altered form. J Exp Med. 1940, 71: 813-838. 10.1084/jem.71.6.813.PubMed CentralView ArticlePubMed
- Chang S, Gu M, Wu F: Establishment of transplanted endometrial neoplasm model in rabbit and its biological features. Prog Obstet Gynecol. 2000, 9: 163-165.
- Duan G, Xu YK, Duan P: Establishment of a rabbit model bearing transplanted endometrial carcinoma and magnetic resonance imaging features of the metastatic lymph nodes. J South Med Univ. 2008, 28: 1716-1719.
- Chen JH, Yao Q, Wang L: Establishment of VX2 breast carcinoma model in rabbit by injecting tumor mass suspension. J Med Colleges PLA. 2004, 19: 161-163.
- Saintigny P, Coulon S, Kambouehner M, Ricci S, Martinot E, Danel C, Breau JL, Bernaudin JF: Realtime RT-PCR detection of CK 19, CK7 and MUCI mRNA for diagnosis of lymph node micrometastases in non-small cell lung carcinoma. Int J Cancer. 2005, 115: 777-782. 10.1002/ijc.20942.View ArticlePubMed
- Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001, 26: 25-35. 10.1247/csf.26.25.View ArticlePubMed
- Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15: 290-298.PubMed CentralPubMed
- Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, Chayama K: Vascular endothelial growth factor C expression predicts Lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer. 2002, 38: 1413-1419. 10.1016/S0959-8049(02)00106-5.View ArticlePubMed
- Straume O, Jackson DG, Akslen LA: Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 2003, 9: 250-256.PubMed
- Ozuysal S, Bilgin T, Ozan H, Kara HF, Oztürk H, Ercan I: Angiogenesis in endometrial carcinoma:correlation with survival and clinicopathologic risk factors. Gynecol Obstet Invest. 2003, 55: 173-177. 10.1159/000071533.View ArticlePubMed
- Verma NK, Dey CS: RNA-mediated gene silencing: mechanisms and its therapeutic applications. J Clin Pharm Ther. 2004, 29: 395-404. 10.1111/j.1365-2710.2004.00579.x.View ArticlePubMed
- Donoghue JF, Lederman FL, Susil BJ, Rogers PA: Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma. Hum Reprod. 2007, 22: 1705-1713. 10.1093/humrep/dem037.View ArticlePubMed
- Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P, Sun Y, Tritsaris K, Hansen AJ, Dissing S, Cao Y: Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA. 2012, 109: 15894-15899. 10.1073/pnas.1208324109.PubMed CentralView ArticlePubMed
- Xie LX, Zhai TT, Yang LP, Yang E, Zhang XH, Chen JY, Zhang H: Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma. Int J Exp Pathol. 2013, 94: 39-46. 10.1111/iep.12005.PubMed CentralView ArticlePubMed
- Tamum M, Ohta Y: Serum vascular endothelial growth factor C level in patients with primary non-small cell lung carcinoma:a possible diagnostic tool for lymph node metastasis. Cancer. 2003, 98: 1217-1222. 10.1002/cncr.11529.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.